84 related articles for article (PubMed ID: 10765129)
1. Prognostic significance of nuclear accumulation of c-myc and mdm2 proteins in synovial sarcoma of the extremities.
Shen J; Scotlandi K; Baldini N; Manara MC; Benini S; Cerisano V; Picci P; Serra M
Oncology; 2000 Apr; 58(3):253-60. PubMed ID: 10765129
[TBL] [Abstract][Full Text] [Related]
2. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.
Oda Y; Sakamoto A; Satio T; Kawauchi S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of bcl-2, c-myc, survivin and tumor grade in synovial sarcoma.
Demır D; Yaman B; Anacak Y; Keçecı B; Kandıloğlu G; Akalin T
Turk Patoloji Derg; 2014; 30(1):55-65. PubMed ID: 24448706
[TBL] [Abstract][Full Text] [Related]
4. Expression of P53, MDM2 and Ki-67 antigens in soft tissue sarcomas.
Szadowska A; Olborski B; Harezga-Bal B; Debiec-Rychter M
Pol J Pathol; 1999; 50(1):9-16. PubMed ID: 10412269
[TBL] [Abstract][Full Text] [Related]
5. p53/MDM-2 immunohistochemical expression correlated with proliferative activity in different subtypes of human sarcomas: a ten-year follow-up study.
Stefanou DG; Nonni AV; Agnantis NJ; Athanassiadou SE; Briassoulis E; Pavlidis N
Anticancer Res; 1998; 18(6B):4673-81. PubMed ID: 9891539
[TBL] [Abstract][Full Text] [Related]
6. High prognostic significance of Mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities.
Würl P; Meye A; Schmidt H; Lautenschläger C; Kalthoff H; Rath FW; Taubert H
Oncogene; 1998 Mar; 16(9):1183-5. PubMed ID: 9528860
[TBL] [Abstract][Full Text] [Related]
7. p53, Mdm2, and c-Myc overexpression is associated with a poor prognosis in aggressive non-Hodgkin's lymphomas.
Pagnano KB; Vassallo J; Lorand-Metze I; Costa FF; Saad ST
Am J Hematol; 2001 Jun; 67(2):84-92. PubMed ID: 11343379
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis.
Shiina H; Igawa M; Shigeno K; Yamasaki Y; Urakami S; Yoneda T; Wada Y; Honda S; Nagasaki M
Oncology; 1999 Apr; 56(3):239-47. PubMed ID: 10202280
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of apoptosis in synovial sarcoma: correlation with clinicopathologic parameters, cell proliferative activity, and expression of apoptosis-related proteins.
Kawauchi S; Fukuda T; Oda Y; Saito T; Oga A; Takeshita M; Yokoyama K; Chuman H; Iwamoto Y; Sasaki K; Tsuneyoshi M
Mod Pathol; 2000 Jul; 13(7):755-65. PubMed ID: 10912935
[TBL] [Abstract][Full Text] [Related]
10. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
[TBL] [Abstract][Full Text] [Related]
11. Alterations of cell cycle regulators in localized synovial sarcoma: A multifactorial study with prognostic implications.
Antonescu CR; Leung DH; Dudas M; Ladanyi M; Brennan M; Woodruff JM; Cordon-Cardo C
Am J Pathol; 2000 Mar; 156(3):977-83. PubMed ID: 10702413
[TBL] [Abstract][Full Text] [Related]
12. Prognostic relevance of Ki-67 antigen and c-myc oncoprotein in malignant fibrous histocytoma.
Brinck U; Stachura J; Kellner S; Schauer A
Anticancer Res; 1995; 15(5B):1915-9. PubMed ID: 8572578
[TBL] [Abstract][Full Text] [Related]
13. Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistological study including 216 soft tissue sarcomas.
Jensen V; Sørensen FB; Bentzen SM; Ladekarl M; Nielsen OS; Keller J; Jensen OM
Histopathology; 1998 Jun; 32(6):536-46. PubMed ID: 9675593
[TBL] [Abstract][Full Text] [Related]
14. A multifactorial prognostic model for adult soft tissue sarcoma considering clinical, histopathological and molecular data.
Würl P; Lautenschläger C; Meye A; Schmidt H; Bache M; Rath FW; Schönfelder M; Taubert H
Anticancer Res; 2000; 20(3B):2065-72. PubMed ID: 10928153
[TBL] [Abstract][Full Text] [Related]
15. Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival.
Pich A; Margaria E; Chiusa L
J Clin Oncol; 2000 Aug; 18(16):2948-56. PubMed ID: 10944127
[TBL] [Abstract][Full Text] [Related]
16. Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor.
Suzuki T; Urano T; Miki Y; Moriya T; Akahira J; Ishida T; Horie K; Inoue S; Sasano H
Cancer Sci; 2007 May; 98(5):644-51. PubMed ID: 17359284
[TBL] [Abstract][Full Text] [Related]
17. Expression of c-myc protein is related to cell proliferation and expression of growth factor receptors in transitional cell bladder cancer.
Lipponen PK
J Pathol; 1995 Feb; 175(2):203-10. PubMed ID: 7738716
[TBL] [Abstract][Full Text] [Related]
18. Malignant mixed Müllerian tumors of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 44 cases.
Blom R; Guerrieri C; Stâl O; Malmström H; Sullivan S; Simonsen E
Gynecol Oncol; 1998 Jan; 68(1):18-24. PubMed ID: 9454654
[TBL] [Abstract][Full Text] [Related]
19. Mitotic count, nuclear atypia, and immunohistochemical determination of Ki-67, c-myc, p21-ras, c-erbB2, and p53 expression in granulosa cell tumors of the ovary: mitotic count and Ki-67 are indicators of poor prognosis.
King LA; Okagaki T; Gallup DG; Twiggs LB; Messing MJ; Carson LF
Gynecol Oncol; 1996 May; 61(2):227-32. PubMed ID: 8626138
[TBL] [Abstract][Full Text] [Related]
20. p53 over-expression identifies a subset of nodal peripheral T-cell lymphomas with a distinctive biological profile and poor clinical outcome.
Pescarmona E; Pignoloni P; Puopolo M; Martelli M; Addesso M; Guglielmi C; Baroni CD
J Pathol; 2001 Oct; 195(3):361-6. PubMed ID: 11673835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
